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To review recent advances in the management strategies of polyarticular course juvenile idiopathic arthritis
(JIA) and identify unanswered questions and avenues for further research.
Recent findings
There is evidence for an early, aggressive, treat-to-target approach for polyarticular JIA. Clinical disease
activity criteria have been recently defined and validated, including criteria for inactive disease and the
juvenile arthritis disease activity score (JADAS). There is a need for evidence-based, defined disease targets
and biomarkers for prediction of response, including targets for remission induction, and guidelines on
drug withdrawal. Recent treatment consensus plans and guidelines are discussed and compared, including
the 2015 NHS England clinical policy statement, the 2014 Childhood Arthritis and Rheumatology
Research Alliance (CARRA) treatment plans and the 2011 American College of Rheumatology (ACR)
guidelines. Evidence for new agents such as tocilizumab, rituximab, golimumab, ustekinumab, certolizumab
and tofacitinib is promising: the recent clinical trials are summarized here. Stratification of individual
patient treatment remains a goal, and predictive biomarkers have been shown to predict success in the
withdrawal of methotrexate therapy.
Summary
There are promising advances in the treatment approaches, disease activity criteria, clinical guidelines,
pharmaceutical choices and individually stratified therapy choices for polyarticular JIA.
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Juvenile idiopathic arthritis is defined as arthritis of
unknown etiology, presenting in children less than
16 years old and persisting for at least 6 weeks. It is
classified by ILAR into six subtypes [1]. Polyarticular
juvenile idiopathic arthritis (pJIA) is defined as dis-
ease involving more than five joints in the first 6
months of disease. A recent Canadian study [2] of
1104 JIA patients showed that patients with pJIA,
particularly rheumatoid factor (RF)-positive pJIA,
were less likely to go into remission, more likely
to have worse outcomes and be treated with steroids
and biologic agents than the other subtypes. Some
studies use the term polyarticular course JIA to
denote any disease with more than five joints
involved, which then may include extended oligo-
articular JIA, enthesitis-related arthritis (ERA),
psoriatic JIA and systemic-onset JIA. For the pur-
poses of this review, data and evidence may be
relevant to all of these subtypes, except for
systemic-onset JIA, which has been extensively
reviewed elsewhere [3
&
]. In this review, we willht © 2015 Wolters Kluwe
rs Kluwer Health, Inc. All rights resediscuss recent advances in the management strat-
egies of pJIA as well as identify unanswered ques-
tions and avenues for further research.
TREAT TO TARGET
Strategies for early, aggressive treatment of adult
inflammatory arthritis now use defined diseaser Health, Inc. All rights reserved.
rved. www.co-rheumatology.com
KEY POINTS
 There is evidence that an early, aggressive treat-to-
target approach in polyarticular course JIA provides
benefit, although evidence-based treatment targets are
not yet fully defined.
 Recent treatment guidelines enable the standardization
of treatment approaches and the subsequent
comparison of treatment efficacy.
 There are promising pediatric data for the use of
tocilizumab in polyarticular JIA; adult studies with the
use of rituximab, certolizumab, golimumab,
ustekinumab and tofacitinib in RA provide new
therapeutic avenues to test in the future in JIA.
 Serum protein MRP8/14 (S100A8/9) is a good
predictor of flare after withdrawal of methotrexate, and
further biomarkers are necessary to stratify a patient’s
prognosis, risk and tailored therapy.
Pediatric and heritable disorderstargets. Tight disease control is beneficial in treat-
ment of adult-onset rheumatoid arthritis (RA) [4–6]
and is included in the adult recommendations [7,8].
Similarly, the pediatric rheumatology community
has recently considered whether this applies to JIA.
The Aggressive Combination Drug Therapy in Very
Early Polyarticular Juvenile Idiopathic Arthritis
(ACUTE-JIA) trial published in 2011 compared bio-
logic combination therapy [methotrexate plus tumor
necrosis factor (TNF)a inhibitor], conventional syn-
thetic DMARD combination (methotrexate, sulpha-
salazine and chloroquine) or methotrexate alone.
Patients had at least five active joints and included
patients with ERA and psoriatic JIA [9]. Patients on
the biologic and methotrexate combination arm
achieved the primary outcome response (ACR Pedi
75), and spent significantly more time in clinically
inactive disease (CID) [10]during the study. Of note is
that only 1 out of 59 patients recruited was RFþ. The
Trial of Early Aggressive Therapy in pJIA trial (TREAT)
[11] enrolled polyarticular RFþ or RF patients
according to the ILAR classification, including
patients that hadapositive family historyofpsoriasis,
but no evidence of psoriasis. Thirty-three to thirty-
nine percent were RFþ. Patients were stratified to
receive: an aggressive regimen of high dose oral pre-
dnisone, subcutaneous methotrexate and etaner-
cept, or subcutaneous methotrexate alone with
placebo oral steroids and placebo etanercept. The
primary end point was achievement of CID [12] at
6 months. Forty percent of those on the aggressive
arm achieved this, vs 23% on methotrexate alone:
this difference did not reach statistical significance
(P¼0.088). The response to methotrexate was higher
than in some studies, which may reflect the use of the Copyright © 2015 Wolters Kluwer 
506 www.co-rheumatology.comsubcutaneous route as first line. There was however a
significant difference in the percentage of patients
achieving an ACR 70 response at 4 months (P¼0.01).
Interestingly, this study found that theonly predictor
of achievement of CID was disease duration at onset
of treatment, not ESR, joint count or RF positivity.
Subsequent analysis reiterated that shorter disease
duration prior to treatment, a robust response at
4 months (with achievement of ACR 70) and more
aggressive therapy result in a higher likelihood and
longer duration of CID in patients with pJIA [13
&
].
This supports earlier evidence that predictors of good
response to methotrexate in JIA include short time to
treatment initiation [14]. Therefore, together several
strands of evidence suggest benefit from early, aggres-
sive therapy for pJIA.DEFINING TARGETS
A major recent advance is the definition and clinical
validation of disease activity in children with JIA
[12,15,16]. These include the Wallace criteria for
CID: no active joints, no uveitis, a normal CRP
and ESR, a physician global assessment of 0 and
morning stiffness for less than 15 min [12]. These
criteria include CID on medication (CID for
>6 months on medication) and CID off medication
(CID for >12 months off medication). The Juvenile
Arthritis Disease Activity Score (JADAS), constructed
from four variables [active joint count (in 10, 27 or
71 joints), patient global assessment, physician
global assessment and ESR], has been validated clini-
cally in JIA [15]. It has also been shown that a three-
item JADAS that excludes use of the ESR (JADAS3)
correlates well with conventional JADAS and that
there is good correlation between the JADAS 10, 27
and 71 [16], suggesting that joint count, combined
with parent/patient and physician’s score, without
ESR measurement may be sufficient for robust
assessment of disease activity.
To have a successful treat-to-target guideline,
there need to be defined targets for disease control
within current practice guidelines [17]. The 2015
NHS England consensus statement on JIA treatment
includes a statement on the goals of therapy [18
&
]
(see below), but evidence-based consensus targets,
including targets for remission induction, mainten-
ance therapy and guidelines on drug withdrawal, are
not yet uniformly defined in JIA [17].TREATMENT PLANS, GUIDELINES AND
RECOMMENDATIONS
There is a lack of consensus-driven, evidence-based
treatment guidelines for pJIA. Owing to this and
variable availability of drugs, there are variations inHealth, Inc. All rights reserved.
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cohorts, therefore, vary in patient recruitment and
treatment regimens, making it more difficult to
directly compare drug efficacy between them. In
2015, NHS England released a policy statement,
‘Biologic Therapies for the treatment of Juvenile
Idiopathic Arthritis’ [18
&
]. This is a clinical guideline
for clinicians and funders, which defined goals of
therapy: ‘to induce and maintain a complete remis-
sion of all symptoms, and thus to allow a child to
achieve normal growth, development, and allow
full participation in school, career, sport and all
other aspects of normal life.’ Intravenous or intra-
articular steroids are recommended for induction,
and methotrexate is advised uniformly for all types
of JIA involving more than four joints as an initial
treatment. Importantly, these guidelines include a
definition of clinical response, clinically inactive
disease, clinical remission on and off medication
and treatment failure. The use of consensus defi-
nitions for these outcomes will provide for the
comparison of countrywide patient cohorts. These
guidelines advise starting a biologic agent in poly-
articular disease where there has been the use of
methotrexate at 15 mg/m2 subcutaneously for at
least 3 months with poor response, except where
axial disease is present, where an anti-TNFa agent
can be started immediately. If CID is not achieved
after 3 months, all patients then start on a TNFa
inhibitor. If there is inadequate response, patients
may switch to a second TNFa inhibitor. With further
lack of effect, the recommendations for polyarticu-
lar RFþ JIA are to start rituximab, whereas tocilizu-
mab or abatacept is recommended for all others who
have failed to respond to two TNFa inhibitors and
are RF.
In 2014, the Childhood Arthritis and Rheuma-
tology Research Alliance (CARRA) developed stand-
ardized consensus-driven treatment plans for
treatment of pJIA. The purpose was to develop
guidelines to enable observational studies and com-
parative effectiveness studies and decrease variabil-
ity of treatment practice. These plans enable
physicians to choose the treatment plan they prefer,
that may then form part of a standardized database
for evaluation. Treatment plans include any JIA that
involves more than four joints, and therefore
includes ERA, psoriatic JIA, undifferentiated JIA
and extended oligoarticular JIA, but specifically
exclude systemic JIA. The three regimens include
the step-up plan (conventional DMARD followed by
biologic after nonresponse), early combination plan
(conventional DMARD and biologic at onset) and
biologic only plan. There are also recommendations
on visit frequency, drug doses and steroid weaning
[19
&
]. Copyright © 2015 Wolters Kluwe
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recommendations [20], which were developed by a
Rand/UCLA appropriateness method, used to assess
benefits vs risks of various therapies when definitive
evidence does not exist to guide treatment. These
are intended more as treatment recommendations,
rather than treatment standardizations as in the
CARRA initiative. The treatment algorithm is
suggested as a recommendation and not a guideline.
For JIA that involves more than four joints (which
includes ERA without sacroiliitis, psoriatic, RFþ and
RF, extended oligoarticular and undifferentiated
JIA), the recommendation is similar to the step-up
plan from CARRA above. Notably, these recommen-
dations also include rituximab for pJIA (especially
RFþ) that is resistant to treatment with TNFa inhi-
bition and abatacept treatment. A large ongoing
European collaborative network (SHARE) is being
developed to standardize care, and create a basic
minimum standard of care across Europe for young
people with JIA: the SHARE recommendations have
not yet been published [21].DRUG ADVANCES AND NEW DRUGS FOR
THE TREATMENT OF POLYARTICULAR
JUVENILE IDIOPATHIC ARTHRITIS
Tocilizumab
The CHERISH trial, published in 2014, was a three-
part, randomized, placebo-controlled, double-blind
withdrawal study [22
&
] of tocilizumab. This trial
enrolled patients with pJIA (RFþ and RF) or
extended oligoarticular JIA with at least five active
joints. Patients had failed or been intolerant to
methotrexate, and may have had a previously inef-
fective biologic agent. In the open-label phase, 89%
of patients achieved an ACR 30 response, and all
core outcome variables measured showed improve-
ment. Optimal dose of tocilizumab was 8 mg/kg if
more than 30 kg and 10 mg/kg if less than 10-kg
body weight. There was a significantly increased rate
of flare in patients on the placebo arm during the
withdrawal phase, compared with those who con-
tinued on tocilizumab. Concurrent methotrexate
was shown to decrease risk of flare in both the
placebo and tocilizumab groups. Patients who had
previously failed another biologic agent were more
likely to flare than biologic-naı¨ve patients in the
withdrawal arm, but 48% of patients with previous
biologic failure still achieved an ACR 70 response on
tocilizumab. These are encouraging results for the
use of tocilizumab in patients with pJIA who have
not achieved a good response with methotrexate
and a TNFa inhibitor. To this end, tocilizumab is
now included in the NHS England guidelines for user Health, Inc. All rights reserved.
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Pediatric and heritable disordersin RF pJIA in patients who have failed two TNFa
inhibitors [18
&
].Rituximab
Rituximab is a chimeric monoclonal antibody to the
B cell antigen CD20, which has been shown to be
effective in adult-onset RA refractory to anti-TNF
therapy [23–25]. There is limited published evi-
dence of use of rituximab for refractory pJIA. Most
reports are case studies or small series and several are
studies in systemic JIA patients [26,27]. An open-
label prospective study [28] on the effectiveness of
rituximab performed in Russia included 55 patients;
84% of these patients had systemic-onset JIA.
Despite this lack of evidence, there is a recommen-
dation from the ACR for the use of rituximab
for severe, unresponsive pJIA [20]. NHS England
guidelines recommend rituximab use in polyarticu-
lar RFþ patients who have failed two TNFa inhibi-
tors [18
&
].Golimumab
Golimumab is a fully humanized monoclonal anti-
body to soluble and transmembranous TNFa. It can
be used as a monthly subcutaneous dose (50 mg for
adults), or a weight-based (2 mg/kg) 8 weekly intra-
venous infusion. This may be useful in JIA, as
weight-based dosing and a relatively long interval
between infusions have advantages in children. It is
biologically similar to infliximab in molecular
weight and constant region sequence, except
that it is fully humanized and not chimeric [29].
GO-KIDS, a recent three part, placebo-controlled,
withdrawal trial showed an 87% ACR 30 response
rate and 36% CID achievement during the open-
label first 16 weeks on golimumab. The study how-
ever failed to meet its primary endpoint, which was
a comparison of rate of flare in responders during
the withdrawal phase between placebo and golimu-
mab (both with concurrent methotrexate). There
was no significant difference in disease flare
between groups, with a sustained ACR 30 response
in both groups (89–95%). Safety profile was accept-
able and injections were tolerable (reported in
abstract form [30]). Further investigation in JIA is
needed. In adults with RA, golimumab has been
shown to be effective in patients with insufficient
response to methotrexate alone as compared with
placebo [31] and in patients on methotrexate who
have had an insufficient response to another TNFa
inhibitor [32]. It has been shown to be effective in
adult psoriatic arthritis [33] and ankylosing spondy-
litis [34], with a safety profile comparable with other
TNFa inhibitors, at least in the short term. Copyright © 2015 Wolters Kluwer 
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Certolizumab pegol is a pegylated anti-TNFa inhibi-
tor that in adults has shown to be effective and have
a good comparative safety profile to other biologic
agents [35–37]. Pegylation enhances the half-life of
the drug and allows a 2–4-week dosing schedule.
There is a clinical trial underway for the use of
certolizumab in children with JIA [38].Ustekinumab
Psoriatic arthritis and ankylosing spondylitis are
unique subtypes of arthritis that have been associ-
ated with IL-23 receptor and other genetic poly-
morphisms [39,40]. The equivalent subcategories
of JIA, namely psoriatic JIA and ERA, can be
challenging to manage, and are less likely than
other subtypes to fully respond to TNFa inhibition.
Ustekinumab is a human monoclonal antibody
directed against the combined interleukin-12 and
interleukin-23 p40 subunit. In adults, ustekinumab
has been shown to be effective and superior to
etanercept for severe plaque psoriasis [41–43] and
effective in adult patients with psoriatic arthritis
who have had a previous failed TNFa inhibitor or
are biologic-naive [44,45]. Results are awaited for a
recent clinical trial on the use of ustekinumab in
adolescents with recalcitrant plaque psoriasis [46].
An open-label proof of concept trial has shown
promising results for the use of ustekinumab in
ankylosing spondylitis [47]. There are currently no
data on the use of ustekinumab for JIA, but the
emerging adult data are promising.Tofacitinib
Tofacitinib is an oral small molecule inhibitor of
the Janus kinase (JAK) and signal transducers and
activators of transcription (STAT) pathways, key
signal transducers that transmit signals from
various cytokine receptors (GMCSF, interleukin-6,
IFN a,U and b, interleukin-10 and others), which
further translocate to the nucleus and regulate
gene expression [48]. Tofacitinib has been shown
to be effective in adult RA refractory to DMARD
and biologic, noninferior to abatacept, and has
been explored as first-line monotherapy vs metho-
trexate [49–52]. It has been approved by the FDA
for treatment of RA refractory to methotrexate but
not by the European Medicines Agency. Safety
concerns exist regarding lymphopenia, risk of
malignancy, elevations in low and high-density
lipoproteins and creatinine [53,54]. There is cur-
rently no evidence for the use of tofacitinib in JIA,
but pharmacokinetic studies in children are under-
way [55].Health, Inc. All rights reserved.
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Given the rapid increase in available choices of
medication for JIA patients refractory to methotrex-
ate, there is an urgent need for evidence-based,
prognostic biomarkers, which provide estimates of
risk of nonresponse to specific drugs. Thus, robust
evidence for high risk of methotrexate failure would
allow clinicians to argue for an early use of biologic,
in combination or alone. Such biomarkers need to
be readily measureable in the pediatric population
for example in small blood volume, or urine. JIA was
the first condition in which a robust biomarker for
use to predict flare upon stopping methotrexate
treatment was discovered. Children who have
reached CID on methotrexate, in whom serum
protein MRP8/14 (S100A8/9) is higher than normal,
have a greater chance of flare after stopping metho-
trexate than those with normal MRP8/14 serum
levels [56]. Progress in the field of predictive bio-
markers for drug response in JIA has been encourag-
ing with genetic, serum and transcriptome studies
[57–61] suggesting that such biomarkers may
become available. Validation of these studies
requires large collaborative efforts. A UK wide con-
sortium CHART (Childhood arthritis response to
treatment) has been established to work in parallel
with large international efforts to address this
unmet need.CONCLUSION
There is evidence that early aggressive treatment for
pJIA is beneficial. There are defined and validated
clinical disease activity criteria, but defined disease
targets necessary for a treat-to-target approach are
lacking in pJIA. Various treatment consensus plans
and guidelines exist, which should allow standard-
ization and direct comparison of drugs and treat-
ment regimens. Tocilizumab and rituximab have
been added to the pJIA armamentarium, and there
are trials underway for novel agents such as golimu-
mab, ustekinumab, certolizumab and tofacitinib in
which the adult data are promising. Stratification
of individual patient treatment remains a goal,
and predictive biomarkers are promising for this
purpose.
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